$4.47
-0.08 (-1.76%)
Open$4.51
Previous Close$4.55
Day High$4.66
Day Low$4.35
52W High$61.72
52W Low$3.80
Volume—
Avg Volume13.7K
Market Cap5.63M
P/E Ratio—
EPS$-197.29
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+532.0% upside
Current
$4.47
$4.47
Target
$28.25
$28.25
$22.50
$28.25 avg
$48.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.10M | 989.8K | 1.05M |
| Net Income | -234,853 | -218,932 | -208,731 |
| Profit Margin | -21.4% | -22.1% | -19.9% |
| EBITDA | -290,262 | -298,722 | -291,498 |
| Free Cash Flow | -192,766 | -116,937 | -167,359 |
| Rev Growth | -6.5% | +19.5% | +20.8% |
| Debt/Equity | 0.95 | 1.14 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |